An assessment by the Statin Cognitive Safety Task Force: 2014 update

Slides:

Advertisements

Similar presentations

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Advertisements

Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements

Hypertension-Lipid Connection: Introduction

Lipid abnormalities in foreign-born and US-born patients in a medical group Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

A clinician's guide to statin drug-drug interactions

Wayne S. Dysinger, MD, MPH, James M. Pappas, MD, MBA

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels† Eli.

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data Steve E. Humphries, PhD, FRCP, Jackie Cooper,

Uric Acid and Long-term Outcomes in CKD

Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

An assessment by the Statin Muscle Safety Task Force: 2014 update

An assessment by the Statin Liver Safety Task Force: 2014 update

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

An assessment by the Statin Diabetes Safety Task Force: 2014 update

Allergy to Surgical Implants

Mild Cognitive Impairment and Mild Dementia: A Clinical Perspective

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

A review of PCSK9 inhibition and its effects beyond LDL receptors

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C- III levels in patients from the MARINE and ANCHOR studies Christie.

Predictors of first-year statin medication discontinuation: A cohort study Heli Halava, MD, Risto Huupponen, MD, PhD, Jaana Pentti, BSc, Mika Kivimäki,

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data Steve E. Humphries, PhD, FRCP, Jackie Cooper,

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

The adequacy of the minimum data set assessment of pain in cognitively impaired nursing home residents Jiska Cohen-Mansfield, PhD, ABPP Journal of Pain.

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

J. W. Balder, MD, PhD, P. J. Lansberg, MD, PhD, M. H. Hof, MSc, A

Temporal Trends in Lipid Screening for Familial Hypercholesterolemia in Youth Catherine J. McNeal, MD, PhD, Justin Zachariah, MD, MPH, Laurel Copeland,

Meredith Kilgore, PhD, Paul Muntner, PhD, J

Emma J. Aarnio, MSc (Pharm), Janne A

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Temporal Trends in Lipid Screening for Familial Hypercholesterolemia in Youth Catherine J. McNeal, MD, PhD, Justin Zachariah, MD, MPH, Laurel Copeland,

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Short Total Sleep Time and Elevated Central Apnea Index are Significant Predictors of Coronary Artery Disease* Tina Constantin, MD, Jeremy R. Anthony,

Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial James D. Otvos,

Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1 Omar Abdel-Razek, MD, Singh N.

An assessment by the Statin Intolerance Panel: 2014 update

Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States Sudhir K. Unni, PhD, MBA, Ruben G.W.

Extended-Release Niacin/Laropiprant Lowers Serum Phosphorus Concentrations in Patients with Type 2 Diabetes and Mild Hyperphosphatemia Andrew G. Bostom,

Daniel E. Weiner, MD, MS American Journal of Kidney Diseases

Redefining Appropriate Treatment Expectations

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Optimal high-density lipoprotein cholesterol cutoff for predicting cardiovascular disease: Comparison of the Korean and US National Health and Nutrition.

The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study Michael Davidson, MD, Michael Stevenson, RPh, PhD, Andrew Hsieh,

Efficacy and Safety of Sebelipase Alfa in Children and Adults with Lysosomal Acid Lipase Deficiency: Results of a Phase 3 Trial† Sandra Rojas-Caro, Barbara.

Focus on the Quadruple Aim: Development of a Resiliency Center to Promote Faculty and Staff Wellness Initiatives Ellen Morrow, MD, Megan Call, PhD, Robin.

Multiple Sclerosis Rehabilitation

Sokunthea Peou, PharmD, Brittany Milliard-Hasting, MD, Sachin A

Patterns of statin use and cholesterol goal attainment in a high-risk cardiovascular population: A retrospective study of primary care electronic medical.

Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials Allan D. Sniderman, MD, James A. Sloand,

Biomarkers of cholesterol homeostasis in a clinical laboratory database sample comprising 667,718 patients Thomas D. Dayspring, MD, FACP, FNLA, Stephen.

Biomarkers of cholesterol homeostasis in a clinical laboratory database sample comprising 667,718 patients Thomas D. Dayspring, MD, FACP, FNLA, Stephen.

Christopher S. Penet, Brian H. Annex, MD, Kelly T. Gregory, R

Measuring quality of life in chronic illness: The functional assessment of chronic illness therapy measurement system David Cella, PhD, Cindy J. Nowinski,

Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia Martine Paquette, MSc, Sophie.

Nicola M. Zetola, MD, Joseph Engelman, MD, Trevor P. Jensen, Jeffrey D

The World and Lipidology as It Relates to Cardiology

Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review Ilse K. Luirink, MD, Jim.

Table of contents The Journal for Nurse Practitioners

Higher long-term adherence to statins in rural patients at high atherosclerotic risk Matthew R. Peverelle, MD, BBiomed, Arul Baradi, MBChB, Sarang Paleri,

Can Low-Radiation Coronary Computed Tomography Angiography Improve Upon Clinical Risk Assessment in Patients with Familial Hypercholesterolemia?* Anna.

A Clinical Pharmacist Patient-Safety Initiative to Reduce Against-Label Prescribing of Statins with Cyclosporine Donald G. Lamprecht, PharmD, Anne M.

Direct Observation of Residents: A Model for an Assessment System

Prediction of Cardiovascular Disease Events by Lipoprotein(a) According to LDL-C in Older High Risk Adults Nathan D. Wong, PhD, Shravanthi R. Gandra,

Clinical effectiveness of laparoscopic fundoplication in a U. S

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis Mary P. McGowan, MD, FNLA

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Presentation transcript:

An assessment by the Statin Cognitive Safety Task Force: 2014 update Carlos H. Rojas-Fernandez, BSc(Pharm), PharmD, Larry B. Goldstein, MD, Allan I. Levey, MD, PhD, Beth A. Taylor, PhD, Vera Bittner, MD, MSPH, FNLA Journal of Clinical Lipidology Volume 8, Issue 3, Pages S5-S16 (May 2014) DOI: 10.1016/j.jacl.2014.02.013 Copyright © 2014 National Lipid Association Terms and Conditions

Figure 1 Evaluation of the patient with cognitive symptoms. CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; MCI, mild cognitive impairment; MS, multiple sclerosis; OTC, over the counter. Journal of Clinical Lipidology 2014 8, S5-S16DOI: (10.1016/j.jacl.2014.02.013) Copyright © 2014 National Lipid Association Terms and Conditions